Onkologie, Hämatologie - Daten und Informationen

11 Gerinnungsstörungen und Thrombosen: 11.9 Literatur

Autor/en: A. Matzdorff, M. Baumhäkel
Letzte Änderung: 01.09.2012
  • Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators.
    Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
    Lancet Oncol 2009;10:943-949. PMID:19726226

  • Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AGG, for the SAVE-ONCO Investigators.
    Semuloprain for thromboprophalaxis in patients receiving chemotherapy for cancer.
    N Engl J Med 2012;366:601-609. PMID:22335737

  • Aschwanden M, Labs KH, Engel H, Schwob A, Jeanneret C, Mueller-Brand J, Jaeger KA.
    Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism.
    Thromb Haemost 2001;85:42-46. PMID:11204585

  • Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I.
    Prediction of venous thromboembolism in cancer patients.
    Blood 2010;116:5377-5382. PMID:20829374

  • Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer TH, Fey MF.
    Coagulation markers predict survival in cancer patients.
    Thromb Haemost 2002;88:745-749. PMID:12428088

  • Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F for the ENOXACAN II investigators.
    Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
    N Engl J Med 2002;346:975-980. PMID:11919306

  • Bern MN, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C.
    Very low doses of warfarin can prevent htormbosis in central venous catheters.
    Ann Intern Med 1990;112:423-428. PMID:2178534

  • British Committee for Standards in Haematology: Writing group: Baglin TP, Brush J, Streiff M.
    Guidelines on use of vena cava filters.
    Br J Haematol 2006;134:590-595. PMID:16869824

  • Caine GJ, Lip GYH.
    Thromboembolism associated with new anti-cancer treatment strategies in combination with conventional chemotherapy: new drugs, old risks?
    Thromb Haemost 2003a;90:567-569. PMID:14515174

  • Caine GJ, Stonelake PS, Rea D, Lip GYH.
    Coagulopathic complications in breast cancer.
    Cancer 2003b;98:1578-1586. PMID:14534872

  • Callander NS, Varki N, Rao LV.
    Immunohistochemical identification of tissue factor in solid tumors.
    Cancer 1992;70:1194-1201. PMID:1381270

  • Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA.
    Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?
    Ann Intern Med. 2008;149:323-333. PMID:18765702

  • Choueiri TK, Schutz FAB, Je Y, Rosenberg JE, Bellmunt J.
    Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials.
    J Clin Oncol 2010;28:2280-2285. PMID:20351323

  • Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW; ARTEMIS Investigators.
    Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
    BMJ 2006;332:325-329. PMID:16439370

  • Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J; ONCENOX Investigators.
    Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
    Clinical and Applied Thrombosis/Hemostasis 2006;12:389-396. PMID:17000884

  • Décousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, Matyas L, Middeldorp S, Sokurenko G, Leizorovicz A; CALISTO Study Group.
    Fondaparinux for the treatment of superficial-vein thrombosis in the legs.
    N Engl J Med 2010;363:1222-1232. PMID:20860504

  • Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Lévesque H, Renaudin JM, Farge D; Working group of the SOR; French National Feberation of Cancer Centers.
    2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group.
    Ann Oncol 2009;20:1459-1471. PMID:19525362

  • Dempfle CE.
    Coagulopathy of sepsis.
    Thromb Haemost 2004;91:213-224. PMID:14961146

  • Douketis JD, Gu C, Piccioli A, Ghirarduzzi A, Pengo V, Prandoni P.
    The long-term risk of cancer in patients with a first episode of venous thromboembolism.
    J Thromb Haemost 2009;7:546-551. PMID:19143921

  • Edwards RL, Silver J, Rickles FR.
    Human tumor procoagulants: registry of the subcommittee on haemostasis and malignancy of the scientific and standardization committee, International Society on Thrombosis and Haemostasis.
    Thromb Haemost 1993;69:205-213. PMID:8456435

  • Elias EG, Shukia SK, Mink IB.
    Heparin and chemotherapy in the management of inoperable lung carcinoma.
    Cancer 1975;36:129-136. PMID:1203841

  • ENOXACAN Study Group.
    Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment.
    Br J Surg 1997;84:1099-1103. PMID:9278651

  • Erpenbeck L, Schön M.
    Deadly allies: the fatal interplay between platelets and metastasizing cancer cells.
    Blood 2010;115:3427-3436. PMID:20194899

  • Fedullo PF, Tapson VF.
    The evaluation of suspected pulmonary embolism.
    N Engl J Med 2003;349:1247-1256. PMID:14507950

  • Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Wieand S, Tan-Chiu E, Ford L, Wolmark N.
    Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    J Natl Cancer Inst 1998;90:1371-1388. PMID:9747868

  • Font C, Farrús B, Vidal L, Caralt TM, Visa L, Mellado B, Tàssies D, Monteagudo J, Reverter JC, Gascon P.
    Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients.
    Ann Oncol 2011;22:2101-2106. PMID:21325446

  • Francis JL, Amirkhosravi A.
    Effect of antihemostatic agents on experimental tumor dissemination.
    Semin Thromb Hemost 2002;28:29-38. PMID:11885023

  • Frank DA, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD.
    The treatment and outcome of cancer patients with thromboses on central venous catheters.
    J Thromb Thrombolysis 2000;10:271-275. PMID:11122548

  • Gasic GJ, Gasic TB, Murophy S.
    Anti-metastatic effect of aspirin.
    Lancet 1972;2(7783):932-933. PMID:4116642

  • Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW; American College of Chest Physicians.
    Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Chest 2008;133(6 Suppl):381S-453S. PMID:18574271

  • Green D, Hull RD, Brant R, Pineo GF.
    Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin.
    Lancet 1992;339:1476. PMID:1351142

  • Guglielmelli T, Bringhen S, Palumbo A.
    Update on the use of defibrotide.
    Expert Opin Biol Ther. 2012 Jan 28. PMID:22283742

  • Hach-Wunderle V.
    Interdisziplinäre S2-Leitlinie. Diagnostik und Therapie der Bein- und Beckenvenenthrombose und der Lungenembolie.
    Phlebologie 2005;34:47-64. PMID:15945147

  • Haddad TC, Greeno EW.
    Chemotherapy-induced thrombosis.
    Thromb Res 2006;118:555-568. PMID:16388837

  • Hirsh J, Lee AYY.
    How we diagnose and treat deep vein thrombosis.
    Blood 2002;99:3102-3110. PMID:11964271

  • Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds).
    SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, URL:http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission,
    posted to the SEER web site, 2011

  • Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G; LITE Trial Investigators.
    Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.
    Am J Med 2006;119:1062-1072. PMID:17145251

  • Hurwitz HI, Saltz LB, van Cutsem E, Cassidy J, Wiedemann J, Sirzén F, Lyman GH, Rohr UP.
    Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies.
    J Clin Oncol 2011;29:1757-1764. PMID:21422411

  • Iversen LH, Thorlacius-Ussing O.
    Systemic coagulation reactivation in recurrence of colorectal cancer.
    Thromb Haemost 2003;89:726-734. PMID:12669128

  • Jorgensen LN, Lausen I, Rasmussen MS, Wille-Jorgensen P, Bergqvist D, Prism Trial Investigators.
    Prolonged thromboprophylaxis with low molecular weight heparin (tinzaparin) following major general surgery primarily for cancer: An individual patient data metaanalysis.
    J Thromb Haemost 2003; 1(Suppl. 1):P1870

  • Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E.
    Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
    J Clin Oncol 2003;21:60-65. PMID:12506171

  • Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RCN.
    Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma.
    Br J Surg 1999;86:890-894. PMID:10417560

  • Kakkar AK, Kadziola Z, Williamson RCN, Levine MN, Low V, Lemoine NR, on Behalf of the Fragmin Advanced Malignancy Outcome Study (FAMOUS) Investigators.
    Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
    J Clin Oncol 2004;22:1944-1948. PMID:15143088

  • Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J.
    Venous thrombosis in cancer patients: insights from the FRONTLINE survey.
    Oncologist 2003;8:381-388. PMID:12897335

  • Kakkar AK, Williamson RCN.
    Prevention of VTE in cancer patients.
    Semin Thromb Hemost 1999;25:239-243. PMID:10357091

  • Kalka C, Spirk D, Siebenroch KA, Metzger U, Tuor P, Sterzing D, Oehy K, Wondberg D, Mouhsine el Y, Gautier E, Kucher N.
    Lack of extended venous thromboembolism prophylaxis in high-risk patients undergoing major orthopaedic or major cancer surgery. Electronic Assessment of VTE Prophylaxis in High-Risk Surgical Patients at Discharge from Swiss Hospitals (ESSENTIAL).
    Thromb Haemost 2009;102:56-61. PMID:20062938

  • Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Gunther A, Engelmann B, Preissner KT.
    Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation.
    Proc Natl Acad Sci USA 2007;104:6388-6393. PMID:17405864

  • Kaźmierczak M, Lewandowski K, Wojtukiewicz MZ, Turowiecka Z, Kołacz E, Lojko A, Skrzydlewska E, Zawilska K, Komarnicki M.
    Cancer procoagulant in patients with adenocarcinomas.
    Blood Coagul Fibrinolysis 2005;16:543-547. PMID:16269926

  • Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians.
    Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Chest 2008;133 (6 Suppl):454S-545S. PMID:18574272

  • Kemkes-Matthes B, Plusczyk T, Lasch HG.
    Coagulation inhibitors in pulmonary cancer patients.
    Thromb Res 1992;65:85-94. PMID:1318586

  • Khorana AA.
    Malignancy, thrombosis, and Trousseau: the case for an eponym.
    J Thromb Haemost 2003;1:2463-2465. PMID:14675077

  • Khorana AA.
    Cancer and thrombosis: implications of published guidelines for clinical practice.
    Ann Oncol 2009;20:1619-1630. PMID:19561038

  • Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW.
    Development and validation of a predictive model for chemotherapy-associated thrombosis.
    Blood 2008;111:4902-4907. PMID:18216292

  • Kim YJ, Borsig L, Han HL, Varki NM, Varki A.
    Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium.
    Am J Pathol. 1999;155:461-472. PMID:10433939

  • Kitchens CS.
    How I treat superficial thrombophlebitis.
    Blood 2011:117:39-44. PMID:20980677

  • Kolbach DN, Sandbrink MW, Hamulyak K, Neumann HA, Prins MH.
    Nonpharmaceutical measures for prevention of post-thrombotic syndrome.
    Cochrane Database Syst Rev 2004; CD004174

  • Kucher N, Spirk D, Baumgartner I, Mazzolai L, Korte W, Nobel D, Banyai M, Bounameaux H.
    Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Ann Oncol 2010;21:931-935. PMID:19828560

  • Kuenen BC, Levi M, Meijers JCM, van Hinsberg VW, Berkhof J, Kakkar AK, hoekman K, Pinedo HM.
    Potential Role of Platelets in Endothelial Damage Observed During Treatment With Cisplatin, Gemcitabine, and the Angiogenesis Inhibitor SU5416.
    J Clin Oncol 2003;21:2192-2198. PMID:12775746

  • Labianca R, Gsparini G, Barni S, Verso M, Bonizzoni E, Brighenti M, Mandala M, Petrelli F, Bianchini C, Perrone T, Agnelli G.
    Prediction of venous thromboembolism in ambulatory patients with cancer receiving chemotherapy: An expanded thromboembolic risk score model.
    J Clin Oncol 29: 2011 (suppl; abstr e19551)
    [Abstract online]

  • Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators.
    Efficacy and safety of low-dose aspirin in polycythemia vera.
    N Engl J Med 2004;350:114-124. PMID:14711910

  • Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR.
    Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
    Cancer. 2005;104:1442-1452. PMID:16116598

  • Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delasements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E, for the Petites Cellules Group.
    Subcutaneous heparin treatment increases survival in small cell lung cancer.
    Cancer 1994;7:38-45. PMID:8004580

  • Lechner D, Weltermann A.
    Pathophysiologie der Chemotherapie-assoziierten Thrombose.
    Hämostaseologie 2009;29:112-120. PMID:19151860

  • Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators.
    Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    N Engl J Med 2003;349:146-153. PMID:12853587

  • Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, Julian JA.
    Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer.
    J Clin Oncol 2006;24:1404-1408. PMID:16549834

  • Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group.
    Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Circulation 2004;110:874-879. PMID:15289368

  • Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA.
    Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.
    Medicine (Baltimore) 1999;78:285-291. PMID:10499070

  • Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology.
    American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer.
    J Clin Oncol 2007;25:5490-5505. PMID:17968019

  • Mandalà M, Falanga A, Roila F, ESMO Guidelines Working Group.
    Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.
    Ann Oncol 2011;22 (Suppl. 6):vi85-vi92. PMID:21908511

  • Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G.
    Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.
    Eur J Cancer 2011 [Epub ahead of print]. PMID:22100906

  • Mathers CD, Loncar D.
    Projections of Global Mortality and Burden of Diesease 2002 to 2030.
    PLoS Medicine 2006;3:e442. PMID:17132052

  • Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA.
    Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer.
    Thromb Haemost 2011;106:371-378. PMID:21713322

  • Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cotta P, Farge D.
    Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer.
    Arch intern Med 2002;162:1729-1735. PMID:12153376

  • Molnar S, Guglielmone H, Lavarda M, Rizzi ML, Jarchum G.
    Procoagulant factors in patients with cancer.
    Hematology 2007;12:555-559. PMID:17852460

  • Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A.
    Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin).
    Thromb Haemost 1996;75:251-253. PMID:8815570

  • Mousa SA, Petersen JL.
    Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence.
    Thromb Haemost 2009;102:258-267. PMID:19652876

  • NCCN Practice Guidelines in Oncology.
    Venous Thromboembolism. V.1.2010.

  • O’Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, Caton A, Duddalwar V, Boswell W, Grabow K, Liebman HA.
    Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning.
    J Thromb Haemost 2011;9:305-311. PMID:20955348

  • Oger E, Bressollette L, Nonent M, Lacut K, Guias B, Couturaud F, Leroyer C, Mottier D.
    High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients.
    Thromb Haemost 2002;88:592-597. PMID:12362229

  • Ornstein LD, Zacharski LR.
    The use of heparin for treating human malignancies.
    Haemostasis 1999;29(suppl.1):48-60. PMID:10629404. DOI:10.1159/000054112

  • Owens AP III, Mackman N.
    Microparticles in hemostasis and thrombosis.
    Circ Res 2011;108:1284-1297. PMID:21566224

  • Pabinger I, Alt-Epping B, Demarmels Biasutti F, Langer F, Wörmann B, Riess H.
    Venöse Thrombembolien bei Tumorpatienten - Leitlinie in Kooperation mit der Gesellschaft für Thrombose- und Hämostaseforschung e. V. und der Deutschen Gesellschaft für Palliativmedizin.
    Hämostaseologie 2011;31:281-290.

  • Pacouret G, Alison D, Pottier JM, Pottier JM, Bertrand P, Charbonnier B.
    Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal venous thrombosis. A prospective study.
    Arch Intern Med. 1997; 157: 305-308. PMID:9040297

  • Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M.
    Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial.
    J Clin Oncol 2011;29:986-993. PMID:21282540

  • Paneesha S, McManus A, Arya R, Scriven N, Farren T, Nokes T, Bacon S, Nieland A, Cooper D, Smith H, O'Shaughnessy D, Rose P; VERITY Investigators.
    Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics.
    Thromb Haemost 2010;103:338-343. PMID:20024496

  • Patel RK, Ramasamy K, Goss D, Deane C, Bonner L, Arya R.
    Ambulatory therapy of patients with free-floating proximal deep vein thrombosis is safe.
    Thromb Haemost 2005;94:1343-1344. PMID:16411421

  • Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, Hahnfeld S, Hilbig A, Stieler J, Riess H.
    The impact of low molecular weight heparin in first-line pancreatic cancer treatment - final results of the CONKO 004 trial.
    Onkologie 2010;33(suppl 6):200, Abstr. #P668

  • Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW.
    Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.
    Lancet 1992;339:441-445. PMID:1346817

  • Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbioni P, Prins MH, Noventa F, Girolami A.
    Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
    Blood 2002;100:3484-3488. PMID:12393647

  • Prandoni P, Noventa F, Quintavalla R, Bova C, Cosmi B, Siragusa S, Bucherini E, Astrorri F, Cuppini S, Valle FD, Lensing AWA, Prins MH, Villalta S, on behalf of the Canano Investigators.
    Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial.
    Blood 2012; 119:1561-1565. PMID:22180438

  • Ramasamy K, Lim ZY, Pagliuca A, Grundy R, Devereux S, Ho AY, Mufti GJ.
    Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT).
    Bone Marrow Transplant. 2006;38:823-824. PMID:17057726

  • Rao LV.
    Tissue factor as a tumor procoagulant.
    Cancer Metastasis Rev 1992;11:249-266. PMID:1423817

  • Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, Nielsen JD, Horn A, Mohn AC, Sømod L, Olsen B; FAME Investigators.
    Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study.
    J Thromb Haemost 2006;4:2384-2390. PMID:16881934

  • Rickles FR, Edwards RL.
    Activation of blood coagulation in cancer: Trousseau’s syndrome revisited.
    Blood 1983;62:14-31. PMID:6407544

  • Sack GH Jr, Levin J, Bell WR.
    Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features.
    Medicine (Baltimore) 1977;56:1-37. PMID:834136

  • Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G.
    Disseminated intravascular coagulation in solid tumors: clinical and pathologic study.
    Thromb Haemost 2001;86:828-833. PMID:11583315

  • Sallah S, Wan JY, Nguyen NP.
    Venous Thrombosis in Patients with Solid Tumors: Determination of Frequency and Characteristics.
    Thromb Haemost 2002; 87: 575-579. PMID:12008937

  • Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson C-G, Turpie AG, Weisslinger N, the Prophylaxis in Medical Patients with Enoxaparin Study Group.
    A comparison of enoxaparin with placebo for the prevevntion of venous thromboembolism in acutely ill medical patients.
    N Engl J Med 1999;341:793-800. PMID:10477777

  • Santos AB, Llamas P, Román A, Prieto E, De Ona R, De Velasco JF, Thomas JF.
    Evaluation of thrombophilic states in myeloma patients receiving thalidomide: a reasonable doubt.
    Br J Haematol 2003;122:159-167. PMID:12823358

  • Savage KJ, Wells PS, Schulz V, Goudie D, Morrow B, Cruickshank M, Kovacs MJ.
    Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
    Thromb Haemost 1999;82:1008-1010. PMID:10494754

  • Schiller H, Bartscht T, Arlt A, Zahn MO, Seifert A, Bruhn T, Bruhn HD, Gieseler F.
    Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro.
    Int J Clin Pharm Therap 2002;40:329-335. PMID:12467301

  • Schulman S, Lindmarker P, for the duration of anticoagulation (DURAC) trial.
    Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism.
    N Engl J Med 2000;342:1953-1958. PMID:10874063

  • Smorenburg SM, van Noorden CJF.
    The complex effects of heparins on cancer progression and metastasis in experimental studies.
    Pharmacol Rev 2001;53:93-105. PMID:11171940

  • Sørensen HT, Johnsen SP.
    Venous thromboembolism and subsequent short-term risk of an occult cancer.
    J Thromb Haemost 2008;6:249-250. PMID:18036185

  • Streiff MB.
    Vena caval filters: a comprehensive review.
    Blood 2000;95:3669-3677. PMID:10845895

  • Sud R, Khorana AA.
    Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model.
    Thromb Res 2009;123(suppl 4):S18-S21. PMID:19303497

  • Swystun LL, Mukherjee S, Liaw PC.
    Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus.
    J Thromb Haemost 2011;9:2313-2321. PMID:21838758

  • Tebbutte NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi E, Strickland AH, Lowenthal RM, Marx G, Karapetis C, Shannon J, Goldstein D, Nayagam SS, Blum R, Chantrill L, Simes RJ, Price TJ; Australasian Gastro-Intestinal Trials Group.
    Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.
    Ann Oncol 2011;22:1834-1838. PMID:21273347

  • Trousseau A.
    Phlegmasia alba dolens.
    In: Troussea A. ed. Clinique medicale de l'Hôtel-Dieu de Paris.
    Paris: Balliere.JB. 1865:654-712

  • van den Berg YW, Osanto S, Reitsma PH, Versteeg HH.
    The relationship between tissue factor and cancer progression: insights from bench and bedside
    Blood Prepublished online November 7, 2011. PMID:22065595

  • van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR.
    Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials.
    Thromb Haemost 2009;101:762-769. PMID:19350123

  • van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR.
    Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer.
    J Clin Oncol 2011a;29:2071-2076. PMID:21502549

  • van Doormaal FF, Terpstra W, van der Griend R, Prins MH, Nijziel MR, Van De Ree MA, Büller HR, Dutilh JC, ten Cate-Hoek A, Van Den Heiligenberg SM, Van Der Meer J, Otten JM.
    Is extensive screening for cancer in idiopathic venous thromboembolism warranted?
    J Thromb Haemost 2011b;9:79-84. PMID:20946181

  • Varki A.
    Trousseau’s syndrome: multiple definitions and multiple mechanisms.
    Blood 2007;110:1723-1729. PMID:17496204

  • Varki NM, Varki A.
    Heparin inhibition of selectinmediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans.
    Semin Thromb Hemost 2002;28:53-66. PMID:11885026

  • Vlachostergios PJ, Daliani DD, Dimopoulos V, Patrikidou A, Voutsadakis IA, Papandreou CN.
    Nonbacterial thrombotic (marantic) endocarditis in a patient with colorectal cancer.
    Onkologie 2010;33:456-459. PMID:20838062

  • Von Tempelhoff GF, Harenberg J, Niemann F, hommer L, Kirkpatrick CJ, Heilmann L.
    Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery.
    Int J Oncol 2000;16:815-824. PMID:10717252

  • Wahrenbrock M, Borsig L, Le D, Varki N, Varki A.
    Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.
    J Clin Invest 2003;112:853-862. PMID:12975470

  • Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ.
    Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.
    N Engl J Med 2003;349:1227-1235. PMID:14507948

  • Wells PS, Anderson DR, Rodger M, Stiell I, Dreyer JF, Bames D, Forgie M, Kovacs G, Ward J, Kovacs MJ.
    Excluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical Model and D-Dimer.
    Ann Intern Med 2001;135:98-107. PMID:11453709

  • Werner J.
    De la phlegmasia alba dolens.
    Thesis. Faculté de médecine de Paris 1860

  • Wienert V, Gerlach H, Gallenkemper G, Kahle B, Marschall M, Rabe E, Stenger D, Stücker M, Waldermann F, Zabel M.
    AWMF S2-Leitlinie: Medizinischer Kompressionsstrumpf. Letzte Überarbeitung 2006.

  • Wittkowsky AK.
    Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis.
    J Thromb Haemost 2006;4:2090-2091. PMID:16961624

  • Zacharski LR, Ornstein DL, Mamourian AC.
    Low-molecular-weight heparin and cancer.
    Sem Thromb Haemost 2000;26 (Suppl.1):69-77. PMID:11011810

  • Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ.
    Thrombotic events in patients with cancer receiving antiangiogenesis agents.
    J Clin Oncol 2009;27:4865-4873. PMID:19704059

Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie, Rehabilitation u. Sozialmedizin d. Deutschen Krebsgesellschaft e.V. [Mehr]
Nach wie vor online verfügbar: die noch nicht aktualisierten Kapitel des Buches "Supportiv- therapie bei malignen Erkrank- ungen", bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag", 2006. [Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: